Corient Private Wealth
LAB icon

Corient Private Wealth’s Standard BioTools LAB Stock Holding History

Corient Private Wealth’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4K Buy
24,740
+11,694
+90% +$11.1K ﹤0.01% 3023
2026
Q1 		$12K Buy
13,046
+46
+0.4% +$56 ﹤0.01% 2799
2025
Q4 		$16.6K Sell
13,000
-20
-0.2% -$27 ﹤0.01% 2629
2025
Q3 		$16.9K Sell
13,020
-4,980
-28% -$6.52K ﹤0.01% 2535
2025
Q2 		$21.6K Buy
18,000
+5,000
+38% +$5.54K ﹤0.01% 2408
2025
Q1 		$14K Hold
13,000
– – ﹤0.01% 2259
2024
Q4 		$22.8K Hold
13,000
– – ﹤0.01% 2309
2024
Q3 		$25.1K Buy
13,000
+3,000
+30% +$5.88K ﹤0.01% 2426
2024
Q2 		$17.7K Buy
+10,000
New +$24.4K ﹤0.01% 2298

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Corient Private Wealth's LAB Position: Q2 2026 in Review

Corient Private Wealth increased its Standard BioTools (LAB) stake by 90% in Q2 2026, buying an estimated $11.1K and bringing the position to 24,740 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Corient Private Wealth first reported a position in LAB in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.1K in Q3 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Corient Private Wealth held 24,740 shares of Standard BioTools worth $20.4K as of Q2 2026.
  • Corient Private Wealth bought 11,694 Standard BioTools shares in Q2 2026, an estimated $11.1K.
  • Standard BioTools made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #3023 holding.
  • Corient Private Wealth first reported a position in Standard BioTools in Q2 2024 and has held it in 9 quarters since.
  • Corient Private Wealth's Standard BioTools position peaked at $25.1K in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.